Latest Insider Transactions at Xenon Pharmaceuticals Inc. (XENE)
This section provides a real-time view of insider transactions for Xenon Pharmaceuticals Inc. (XENE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Xenon Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Xenon Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2022
|
James R. Empfield EVP, Drug Discovery |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+38.75%
|
$195,000
$3.93 P/Share
|
|
Mar 08
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
14,551
-1.27%
|
$363,775
$25.96 P/Share
|
|
Mar 07
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Open market or private sale
|
Direct |
32,853
-39.93%
|
$985,590
$30.58 P/Share
|
|
Mar 07
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
9,647
-11.42%
|
$289,410
$30.23 P/Share
|
|
Mar 07
2022
|
James R. Empfield EVP, Drug Discovery |
BUY
Exercise of conversion of derivative security
|
Direct |
42,500
+30.12%
|
$297,500
$7.58 P/Share
|
|
Mar 07
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
31,086
-2.06%
|
$932,580
$30.51 P/Share
|
|
Mar 07
2022
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
1,990
-0.86%
|
$59,700
$30.23 P/Share
|
|
Mar 07
2022
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
20,576
+8.19%
|
$61,728
$3.67 P/Share
|
|
Mar 04
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Open market or private sale
|
Direct |
18,315
-64.68%
|
$549,450
$30.79 P/Share
|
|
Mar 04
2022
|
James R. Empfield EVP, Drug Discovery |
SELL
Payment of exercise price or tax liability
|
Direct |
6,685
-19.1%
|
$207,235
$31.42 P/Share
|
|
Mar 04
2022
|
James R. Empfield EVP, Drug Discovery |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+41.67%
|
$200,000
$8.4 P/Share
|
|
Mar 04
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
21,710
-18.4%
|
$651,300
$30.5 P/Share
|
|
Mar 04
2022
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
7,406
+8.62%
|
$22,218
$3.67 P/Share
|
|
Mar 04
2022
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-2.08%
|
$21,576
$31.42 P/Share
|
|
Mar 04
2022
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
9,325
-2.15%
|
$279,750
$30.61 P/Share
|
|
Mar 04
2022
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-0.44%
|
$29,853
$31.42 P/Share
|
|
Mar 04
2022
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
10,288
+4.46%
|
$30,864
$3.67 P/Share
|
|
Jan 21
2022
|
Christopher John Kenney Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
700
+50.0%
|
$19,600
$28.81 P/Share
|
|
Dec 15
2021
|
Mohammad Azab |
BUY
Exercise of conversion of derivative security
|
Direct |
3,086
+4.41%
|
$9,258
$3.67 P/Share
|
|
Dec 08
2021
|
Gary Patou |
BUY
Exercise of conversion of derivative security
|
Direct |
2,057
+7.43%
|
$6,171
$3.67 P/Share
|
|
Dec 06
2021
|
Christopher Von Seggern Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$96,000
$24.4 P/Share
|
|
Nov 15
2021
|
Simon N. Pimstone |
SELL
Open market or private sale
|
Direct |
17,557
-7.71%
|
$544,267
$31.33 P/Share
|
|
May 28
2021
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
6,067
-8.26%
|
$109,206
$18.81 P/Share
|
|
May 28
2021
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
4,216
-6.18%
|
$75,888
$18.91 P/Share
|
|
May 28
2021
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
25,719
+27.29%
|
$77,157
$3.81 P/Share
|
|
May 27
2021
|
Frank A Holler Director |
SELL
Open market or private sale
|
Direct |
11,064
-3.62%
|
$199,152
$18.69 P/Share
|
|
May 27
2021
|
Frank A Holler Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,418
-2.04%
|
$115,524
$18.88 P/Share
|
|
May 27
2021
|
Frank A Holler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
39,094
+10.36%
|
$117,282
$3.76 P/Share
|
|
May 24
2021
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
5,076
-2.18%
|
$96,444
$19.17 P/Share
|
|
May 24
2021
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
22,633
+8.86%
|
$67,899
$3.76 P/Share
|
|
May 18
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.92%
|
$10,500
$3.85 P/Share
|
|
May 18
2021
|
Michael M Tarnow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,229
+3.46%
|
$24,687
$3.74 P/Share
|
|
Mar 17
2021
|
Gary Patou |
BUY
Small Acquisition
|
Indirect |
100
+50.0%
|
$1,900
$19.49 P/Share
|
|
Feb 18
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
41,152
+19.75%
|
$123,456
$3.18 P/Share
|
|
Feb 16
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,144
+4.36%
|
$10,288
$2.68 P/Share
|
|
Dec 15
2020
|
Mohammad Azab |
BUY
Exercise of conversion of derivative security
|
Direct |
3,086
+4.62%
|
$9,258
$3.76 P/Share
|
|
Oct 28
2020
|
Gary Patou |
BUY
Exercise of conversion of derivative security
|
Direct |
2,057
+8.03%
|
$6,171
$3.76 P/Share
|
|
Oct 28
2020
|
Michael M Tarnow Director |
SELL
Bona fide gift
|
Direct |
10,288
-12.86%
|
-
|
|
Oct 28
2020
|
Michael M Tarnow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,288
+6.24%
|
$30,864
$3.76 P/Share
|
|
Mar 27
2018
|
Bvf Partners L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,437,000
-79.94%
|
-
|